Medicina
Facultad
Christie Hospital NHS Foundation Trust
Mánchester, Reino UnidoPublicaciones en colaboración con investigadores/as de Christie Hospital NHS Foundation Trust (87)
2024
-
High prevalence of venous thrombotic events in Cushing’s syndrome: data from ERCUSYN and details in relation to surgery
European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 75-85
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion (American Journal of Clinical Dermatology, (2023), 24, 1, (5-14), 10.1007/s40257-022-00732-w)
American Journal of Clinical Dermatology
-
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Journal of Hematology and Oncology, Vol. 16, Núm. 1
-
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study
The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194
-
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
BMC Cancer, Vol. 23, Núm. 1
-
Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 4, pp. 680-688
-
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
European Urology
-
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
European Journal of Cancer
-
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
American Journal of Clinical Dermatology, Vol. 24, Núm. 1, pp. 5-14
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10378, pp. 733-746
2022
-
Code of practice needed for samples donated by trial participants
The Lancet Oncology
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1415-1427
-
ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors
Journal of Neuroendocrinology, Vol. 34, Núm. 3
-
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487
-
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
Gynecologic Oncology, Vol. 165, Núm. 1, pp. 40-48
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
British Journal of Cancer, Vol. 126, Núm. 11, pp. 1548-1554
-
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311
-
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
ESMO Open, Vol. 7, Núm. 2